Non-steroidal mineralocorticoid receptor antagonist finerenone inhibits peritoneal fibrosis induced by high-glucose dialysate via regulating enhancer of zeste homolog 2 (EZH2) expression.

Finerenone, a novel high-selective aldosterone receptor antagonist, exhibits powerful anti-inflammatory and antifibrotic effects in previous researches. The aim of our study was to investigate of it on peritoneal fibrosis. In our current research, we found that high glucose could induce epithelial mesothelial transformation (EMT) of peritoneal mesothelial cells (HPMCs). Under high glucose stimulation, the addition of finerenone could alleviate high glucose induced EMT and disordered cytoskeleton rearrangement in HPMCs. Moreover, finerenone decreased the expression of enhancer of zeste homolog 2 (EZH2). Results of rescue experiment showed that after overexpression of EZH2 in the presence of finerenone, the protective effect of finerenone on EMT, migration capacity and cytoskeleton rearrangement was counteracted by EZH2 overexpression. The above results have also been demonstrated in experiments. These findings imply that finerenone could alleviate EMT and peritoneal fibrosis regulating EZH2. More studies are needed to validate it and explore further mechanism.